CoLucid Pharmaceuticals Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: Durham NC United States (2005)
Status: Acquired by Eli Lilly (2017)

Organization Overview

First Clinical Trial
2006
NCT00384774
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CoLucid Pharmaceuticals | CoLucid Pharmaceuticals Inc. | CoLucid Pharmaceuticals Inc, USA

Active Ingredients

Drugs in Phase 3 Trials (1)

lasmiditan (Reyvow) (11 trials)

Drugs in Phase 1 Trials (3)

alprazolam (1 trial)

moxifloxacin (avelox) (1 trial)

sumatriptan (zecuity) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Migraine Disorders (Phase 3)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 4